A review by Kakinoki et al. qualitatively found that CD20 staining intensity roughly correlated with the cancer’s response to therapy, with T cell lymphomas that had stronger CD20 expression appearing to enter remission more readily compared to others that displayed weak or variable CD20 expression [47]. This evidence concerns the gene MS4A1 and cancer.